Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aprogen’s Biosimilar Remicade To Hit Japan Next Year?

This article was originally published in PharmAsia News

Executive Summary

South Korea-based biotech firm Aprogen's biosimilar version of Remicade (Johnson & Johnson's infliximab) is set to complete a Phase III clinical study in Japan as early as this month. The company’s Japanese partner will then file for local regulatory approval immediately after completing the trial and aims to launch the product in the country in the latter half of next year.


Related Content

Binex, Tongfang Rework Deal Amid Strained Korea-China Ties
Biosimilar Bummer: FDA Postpones Celltrion Infliximab Advisory Committee


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts